Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer

Author:

Clarke Noel W.1,Armstrong Andrew J.2,Thiery-Vuillemin Antoine3,Oya Mototsugu4,Shore Neal5,Loredo Eugenia6,Procopio Giuseppe7,de Menezes Juliana8,Girotto Gustavo9,Arslan Cagatay10,Mehra Niven11,Parnis Francis12,Brown Emma13,Schlürmann Friederike14,Joung Jae Y.15,Sugimoto Mikio16,Virizuela Juan A.17,Emmenegger Urban18,Navratil Jiri19,Buchschacher Gary L.20,Poehlein Christian21,Harrington Elizabeth A.22,Desai Chintu23,Kang Jinyu24,Saad Fred25

Affiliation:

1. The Christie and Salford Royal Hospital NHS Foundation Trusts, University of Manchester, Manchester, United Kingdom

2. Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University, Durham, NC

3. Centre Hospitalier Régional Universitaire Hôpital Jean-Minjoz, Besançon, France

4. Keio University School of Medicine, Tokyo

5. Carolina Urologic Research Center, Myrtle Beach, SC

6. Centro de Investigaciones Clinicas Viña del Mar, Valparaíso, Chile

7. Fondazione Istituto Nazionale Tumori Milano, Milan

8. Hospital Nossa Senhora da Conceição, Porte Alegre, Brazil

9. Hospital de Base São José do Rio Preto, São José do Rio Preto, Brazil

10. Izmir Economy University Medical Park Hospital, Karsiyaka, Turkey

11. Radboud Universitair Medisch Centrum, Nijmegen, Netherlands

12. Ashford Cancer Centre Research, Adelaide, South Australia

13. University Hospital Southampton, Southampton, United Kingdom

14. Centre Hospitalier Intercommunal de Cornouaille, Quimper, France

15. National Cancer Center, Goyang, South Korea

16. Kagawa University Hospital, Kagawa, Japan

17. Hospital Universitario Virgen Macarena, Seville, Spain

18. Sunnybrook Research Institute and Odette Cancer Centre, Toronto

19. Masaryk Memorial Cancer Institute, Brno, Czech Republic

20. Kaiser Permanente Southern California, Los Angeles

21. Merck & Co., Inc., Rahway, NJ

22. Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom

23. Global Medicines Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom

24. Global Medicines Development, Oncology R&D, AstraZeneca, Gaithersburg, MD

25. Centre Hospitalier de l’Universite de Montreal, Montreal

Publisher

Massachusetts Medical Society

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3